^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dactinomycin (Topoisomerase II inhibitor, RNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A PHASE 2A STUDY ON THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN-D IN PATIENTS WITH NPM1-MUTATED AML AGED =70 YEARS AND/OR UNFIT FOR INTENSIVE CHEMOTHERAPY, EITHER NEWLY DIAGNOSED OR PREVIOUSLY TREATED WITH HYPOMETHYLATING AGENTS STUDIO DI FASE 2A SULLA ATTIVITA’ CLINICA E SICUREZZA DI ACTINOMICINA D IN PAZIENTI CON LEUCEMIA MIELOIDE ACUTA CON MUTAZIONE DEL GENE NPM1 DI ETA’ UGUALE O SUPERIORE A 70 ANNI E/O NON IDONEI A CHEMIOTERAPIA STANDARD, CON MALATTIA DI NUOVA DIAGNOSI O GIA’ TRATTATA CON FARMACI IPOMETILANTI
Excerpt:
...Diagnosis of NPM1-mutated AML based on detection of NPM1 mutations at molecular analysis58 and/or demonstration of aberrant cytoplasmic expression of nucleophosmin at immunohistochemistry18. ...
Trial ID:
Source:
Title:
A phase 2a study of the clinical activity and safety of actinomycin D in patients with NPM1-wild type AML (other than APL) aged = 70 years old and/or unfit for intensive chemotherapy, either newly diagnosed or previously treated with hypometylating agents Studio di fase 2a sulla attivita’ clinica e sicurezza di Actinomicina D in pazienti con leucemia mieloide acuta senza mutazione del gene npm1 (ad eccezione della leucemia acuta promielocitica) di eta’ uguale o superiore a 70 anni e/o non idonei a chemioterapia standard, con malattia di nuova diagnosi o gia’ trattata con farmaci ipometilanti
Excerpt:
...Diagnosis of AML with NPM1-wild type genotype (lack of NPM1 mutations as detected at molecular analysis35 and/or at immunohistochemistry24). ...
Trial ID:
More C2 evidence
Source:
Title:
A PHASE II STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN D IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH NUCLEOPHOSMIN (NPM1) GENE MUTATION
Excerpt:
...Male or female NPM1-mutated AML patients ≥ 18 years of age 2. ...
Trial ID:
Less C2 evidence
Source:
Title:
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
Published date:
03/02/2021
Excerpt:
We also provide evidence that the activity of dactinomycin associates with nucleolar stress both in vitro and in vivo in patients. Finally, we show that low-dose dactinomycin generates more efficient stress response in cells expressing NPM1 mutant compared to wild-type cells, suggesting that NPM1-mutated AML may be more sensitive to nucleolar stress.
DOI:
10.1038/s41375-021-01192-7
